73
After percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is recommended for 6 months in stable coronary artery disease1,2 and 12 months in acute coronary syndromes.3,4 Over the past decade, several trials have tested shorter regimens.5 Most of these trials were non-inferiority trials powered for composite endpoints combining ischaemic and bleeding events—so-called net adverse clinical events. This design often suggested non-inferiority of abbreviated DAPT, but uncertainty remains regarding true protection from major adverse cardiac or cerebrovascular events.
